Monte Rosa Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $60,647 | $9,216 | $4,695 | $1,064 |
Gross Profit | 60,647 | 9,216 | 2,635 | -833 |
EBITDA | 15,065 | -24,424 | -30,582 | -33,049 |
EBIT | 13,004 | -26,527 | -32,642 | -34,946 |
Net Income | 13,437 | -23,859 | -30,310 | -31,968 |
Net Change In Cash | 60,647 | 9,216 | 4,695 | 1,064 |
Free Cash Flow | 128,739 | -21,393 | -29,788 | -39,549 |
Cash | 224,254 | 125,575 | 108,847 | 99,752 |
Basic Shares | 61,436 | 82,011 | 71,233 | 60,156 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $75,622 | $0 | $0 | $0 |
Gross Profit | 75,622 | -6,222 | -8,559 | -2,132 |
EBITDA | -81,112 | -137,089 | -99,942 | -70,750 |
EBIT | -143,311 | -108,501 | -72,882 | |
Net Income | -72,700 | -135,352 | -104,618 | -71,942 |
Net Change In Cash | 75,622 | 0 | 0 | 0 |
Cost of Revenue | -291,219 | 308,546 | ||
Free Cash Flow | 38,008 | -62,843 | -105,377 | -69,095 |
Cash | 224,254 | 128,101 | 54,912 | 346,071 |
Basic Shares | 73,910 | 51,396 | 47,227 | 46,535 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $0.27 |
2024-09-30 | -$0.29 |
2024-06-30 | -$0.43 |
2024-03-31 | -$0.53 |
